---
title: "Travere Therapeutics Director Sells 10,000 Shares"
date: "2025-02-11 07:10:01"
summary: "Reporter NameBaynes Roy D.RelationshipDirectorTypeSellAmount$220,000SEC FilingForm 4Roy D. Baynes, a Director at Travere Therapeutics, sold 10,000 shares of Common Stock on February 6, 2025, at a price of $22.0 per share, totaling $220,000. Following this transaction, Baynes directly owns 31,000 shares of the company. The sale was executed under a pre-arranged..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

| Reporter Name | Baynes Roy D. |
| --- | --- |
| Relationship | Director |
| Type | Sell |
| Amount | $220,000 |
| SEC Filing | [Form 4](https://www.sec.gov/Archives/edgar/data/1680739/000141588925003529/xslF345X05/form4-02102025_110214.xml) |

Roy D. Baynes, a Director at Travere Therapeutics, sold 10,000 shares of Common Stock on February 6, 2025, at a price of $22.0 per share, totaling $220,000. Following this transaction, Baynes directly owns 31,000 shares of the company. The sale was executed under a pre-arranged 10b5-1 trading plan established on August 16, 2024.

SEC Filing: [Travere Therapeutics, Inc. [ TVTX ] - Form 4 - Feb. 10, 2025](https://www.sec.gov/Archives/edgar/data/1680739/000141588925003529/xslF345X05/form4-02102025_110214.xml)

[TradingView](https://www.tradingview.com/news/tradingview:d26fcd0ff508a:0-travere-therapeutics-director-sells-10-000-shares/)
